Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: PRO-542, Progenics Pharmaceuticals inc.

M Mukhtar1, Z Parveen, R J Pomerantz

  • 1Dorrance H Hamilton Laboratories, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. Muhammad.Mukhtar@mail.tju.edu

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling difenoconazole and flusilazole resistance, fitness penalty and phenotypic stability in Venturia inaequalis.

Scientific reports·2025
Same author

PRDM16, LRP1 and TRPM8 genetic polymorphisms are risk factor for Pakistani migraine patients.

Saudi journal of biological sciences·2021
Same author

Gene expression of RAGE, HMGB1 and BAX as Genetic markers of diabetic myocardial infarction in population of Pakistan.

Journal of biological regulators and homeostatic agents·2020
Same author

Correction to: Screening and computational analysis of colorectal associated non-synonymous polymorphism in CTNNB1 gene in Pakistani population.

BMC medical genetics·2020
Same author

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells.

International journal of cancer·2016
Same author

Maternal and foetal outcome of 206 high risk pregnancy cases in border guard hospital, dhaka.

Mymensingh medical journal : MMJ·2015

Progenics

Area of Science:

  • Biotechnology
  • Virology
  • Immunology

Background:

  • Progenics's rCD4-IgG2 (PRO-542) is an investigational antiviral therapy.
  • PRO-542 utilizes Universal Antiviral Binding (UnAB) technology for human immunodeficiency virus type I (HIV-1) treatment.
  • The drug is currently undergoing Phase I/II clinical trials.

Purpose of the Study:

  • To develop and evaluate PRO-542 as a potential treatment for HIV-1 infection.
  • To establish cost-effective manufacturing methods for PRO-542.

Main Methods:

  • Development of PRO-542 using UnAB technology.
  • Clinical trials for HIV-1 treatment.
  • Collaboration with research institutions for drug evaluation.
  • Development of transgenic goats for PRO-542 production in milk.

Related Experiment Videos

  • Optimization of PRO-542 production in transgenic dairy animals.

    • Main Results:

    • PRO-542 is in Phase I/II clinical trials for HIV-1.
    • Grants received to fund clinical evaluation and development.
    • Partnership established for transgenic production of PRO-542.
    • Research ongoing for cost-effective manufacturing.

    Conclusions:

    • PRO-542 shows promise as an HIV-1 therapeutic.
    • Transgenic technology is being explored for efficient drug production.
    • Further clinical evaluation and manufacturing optimization are planned.